Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
AptaBio Therapeutics Inc banner
A

AptaBio Therapeutics Inc
KOSDAQ:293780

Watchlist Manager
AptaBio Therapeutics Inc
KOSDAQ:293780
Watchlist
Price: 7 850 KRW -1.01% Market Closed
Market Cap: ₩220.5B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
AptaBio Therapeutics Inc

There are no price targets for AptaBio Therapeutics Inc.
Lowest Forecast
Wall Street Target
Not Available
Average Forecast
Wall Street Target
Not Available
Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
AptaBio Therapeutics Inc Competitors:
Price Targets
CIGI
Colliers International Group Inc
17% Upside
UFPT
UFP Technologies Inc
20% Upside
ITRN
Ituran Location and Control Ltd
6% Upside
SUPN
Supernus Pharmaceuticals Inc
23% Upside
CIGI
Colliers International Group Inc
17% Upside
UFPT
UFP Technologies Inc
20% Upside
ITRN
Ituran Location and Control Ltd
6% Upside
SUPN
Supernus Pharmaceuticals Inc
23% Upside
FSFG
First Savings Financial Group Inc
-1% Downside
WASH
Washington Trust Bancorp Inc
-3% Downside
HOTH
Hoth Therapeutics Inc
400% Upside

Revenue
Forecast

15% / Year
Past Growth
-21% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
15% / Year
Past Growth
-21% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 6 years the compound annual growth rate for AptaBio Therapeutics Inc's revenue is 15%. The projected CAGR for the next 5 years is -21%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AptaBio Therapeutics Inc's stock price target?
Not Available

AptaBio Therapeutics Inc doesn't have any price targets made by Wall Street professionals.

What is AptaBio Therapeutics Inc's Revenue forecast?
Projected CAGR
-21%

For the last 6 years the compound annual growth rate for AptaBio Therapeutics Inc's revenue is 15%. The projected CAGR for the next 5 years is -21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 318,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.